1. Pink Sheet
  2. >>Geography
  3. >>Europe

Janssen’s Spravato Clears Hurdles To Secure EU Approval

Written Interventions By Third Parties Had Earlier Raised Uncertainty

 
• By Vibha Sharma

Spravato has been approved for treatment-resistant depression in the EU notwithstanding last-minute objections by third parties.

DEPRESSION miserable depressed , Depression and its consequences, Depressed emotions concept , alone in depression - Image
Janssen’s New Antidepressant Is Approved For EU-Wide Use • Source: Shutterstock

Janssen’s controversial new drug for treatment-resistant depression, Spravato (esketamine), has been authorized for EU-wide use despite late-stage interventions from third-parties who were presumably unhappy with some aspects of the product's likely approval.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

EU ‘Can’t Expect Industry To Give Up Proprietary Insights’ Under Health Data & Clinical Trials Regulations

 
• By Eliza Slawther

Both the EU Clinical Trials Regulation and the European Health Data Space Regulation have the potential to improve harmonization and be highly valuable for industry – but the importance of protecting company data will be paramount, a life sciences consultant says.

How Tumult At US FDA Could Impact Merger and Acquisition Strategy

 
• By Joseph Haas and Nielsen Hobbs

With review and development uncertainly increasing, "it’s going to take longer for certain targets … to progress to a place where they’ve been derisked enough that big pharma is ready to write a big check," said Andrew Goodman of Paul Hastings.